Footnotes:
C1: drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drugs Regulations
C2: drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drugs Regulations
C3: drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drugs Regulations
C4: drug is in the Controlled Drugs and Substances Act
C5: drug is in the Regulations Under CDSA
CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
D: drug references federal Schedule "D" for Biologics
F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR: drug has not been reviewed by NDSAC
R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
U: drug has been reviewed by NDSAC and is unscheduled
"summary": a summary of the recommendation has been developed and is posted